VimRx, Columbia University deal

VMRX terminated its 1997 agreement with the university to develop disease gene identification technologies through their VIMRx Genomics Inc. joint venture. The venture also dissolved under the termination. VMRX returned to the university its rights to develop VM201, a Factor IXa inhibitor, and Bcl-6 and MUM-1, two cancer genes implicated in non-Hodgkin's lymphoma and multiple myeloma, respectively. VMRX also will not acquire the RAGE (receptor for advanced glycation end products) target from the university. VMRX will pay the university $900,000 to cover existing obligations. ...